Cartesian Therapeutics Inc. Market Cap ($172.18 Million)
Market Cap & Net Worth: Cartesian Therapeutics Inc. (RNAC)
Cartesian Therapeutics Inc. market cap. Cartesian Therapeutics Inc. (NASDAQ:RNAC) has a market capitalization of $172.18 Million ($172.18 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #16923 globally and #4031 in its home market, demonstrating a 2.07% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cartesian Therapeutics Inc.'s stock price $6.41 by its total outstanding shares 29381514 (29.38 Million). Also see RNAC cash generation efficiency for how efficiently the company converts equity into cash flow.
Cartesian Therapeutics Inc. Market Cap History (2016–2026)
Cartesian Therapeutics Inc. market cap history from 2016 to 2026. Data shows change from $15.12 Billion to $188.34 Million (-33.18% CAGR). Check today's stock price for Cartesian Therapeutics Inc. for real-time trading data and today's change.
Index Memberships
Cartesian Therapeutics Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #456 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1655 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.83 Trillion | 0.01% | #225 of 263 |
Weight: Cartesian Therapeutics Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cartesian Therapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cartesian Therapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Cartesian Therapeutics Inc. (RNAC) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
75.74x
Cartesian Therapeutics Inc.'s market cap is 75.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $15.12 Billion | $8.08 Million | -$36.21 Million | 1870.20x | N/A |
| 2017 | $8.65 Billion | $207.00K | -$65.32 Million | 41772.85x | N/A |
| 2018 | $2.34 Billion | $903.00K | -$65.34 Million | 2596.51x | N/A |
| 2019 | $2.10 Billion | $6.68 Million | -$55.35 Million | 314.19x | N/A |
| 2020 | $2.67 Billion | $16.60 Million | -$68.88 Million | 160.92x | N/A |
| 2021 | $2.87 Billion | $85.08 Million | -$25.69 Million | 33.78x | N/A |
| 2022 | $996.03 Million | $110.78 Million | $35.38 Million | 8.99x | 28.15x |
| 2023 | $607.67 Million | $26.00 Million | -$219.71 Million | 23.37x | N/A |
| 2024 | $526.22 Million | $38.91 Million | -$77.42 Million | 13.52x | N/A |
| 2025 | $211.84 Million | $2.80 Million | -$130.30 Million | 75.74x | N/A |
Competitor Companies of RNAC by Market Capitalization
Companies near Cartesian Therapeutics Inc. in the global market cap rankings as of November 4, 2026. Also see total assets of Cartesian Therapeutics Inc. for a full breakdown of the balance sheet.
Key companies related to Cartesian Therapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Cartesian Therapeutics Inc. (2016–2026)
Market capitalization of Cartesian Therapeutics Inc. from 2016 to today. Between 2016 and today, Cartesian Therapeutics Inc.'s market cap moved from $15.12 Billion to $ 188.34 Million, with a yearly change of -33.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $188.34 Million | -11.10% |
| 2025 | $211.84 Million | -59.74% |
| 2024 | $526.22 Million | -13.40% |
| 2023 | $607.67 Million | -38.99% |
| 2022 | $996.03 Million | -65.34% |
| 2021 | $2.87 Billion | +7.59% |
| 2020 | $2.67 Billion | +27.31% |
| 2019 | $2.10 Billion | -10.53% |
| 2018 | $2.34 Billion | -72.88% |
| 2017 | $8.65 Billion | -42.80% |
| 2016 | $15.12 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Cartesian Therapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $172.18 Million USD |
| MoneyControl | $172.18 Million USD |
| MarketWatch | $172.18 Million USD |
| marketcap.company | $172.18 Million USD |
| Reuters | $172.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune disease… Read more